Anlotinib Plus Anti-PD-1 Antibody AK105 for Advanced Pancreatic Cancer

Anlotinib Plus Anti-PD-1 Antibody AK105 as Third or More-line Therapy for Advanced Pancreatic Cancer: a Prospective, Single-arm, Open-label, Pilot Study

This study was designed to explore the clinical efficacy of Anlotinib combined with Anti-PD-1 antibody AK105 in the treatment of third- and above -line advanced pancreatic cancer patients, in order to find a better therapy strategy for pancreatic cancer patients.

Inclusion Criteria:

• locally advanced or metastatic pancreatic cancer (PC),
• histologically or cytologically proven diagnosis of adenocarcinoma or adenosquamous carcinoma,
• failed to second-line chemotherapy for PC,
• 18-75 years of age,
• an Eastern Cooperative Oncology Group performance status score of 0 to 1,
• adequate organ functions

Exclusion Criteria:

• had received PD 1 /CTLA 4 antibody treatment
• had received anti-VEGFR inhibitors or antibodies